Epigenetic therapy in hematological cancers

APMIS. 2019 May;127(5):316-328. doi: 10.1111/apm.12906. Epub 2019 Mar 12.

Abstract

The increasing depth of knowledge about cancer biology throughout the last decades, has underlined the importance of not only genetic aberrations, but also epigenetic abnormalities in cancer cells. The extensive exploration of the cancer epigenome has provided insights into key pathways involved in tumorigenesis, as well as has allowed the development of novel epigenetic therapies. In this review, we will present the important role of epigenetic alterations in hematological diseases, with special focus on epigenetically-based targeting of hematological malignancies.

Keywords: Epigenetics; hematology; leukemia; lymphoma; myeloma.

Publication types

  • Review

MeSH terms

  • DNA (Cytosine-5-)-Methyltransferase 1 / antagonists & inhibitors
  • DNA Methylation
  • Epigenesis, Genetic*
  • Hematologic Neoplasms / drug therapy
  • Hematologic Neoplasms / genetics*
  • Histone Deacetylase Inhibitors / therapeutic use
  • Histones / metabolism
  • Humans

Substances

  • Histone Deacetylase Inhibitors
  • Histones
  • DNA (Cytosine-5-)-Methyltransferase 1